Reducing infections and stigma: Pop-up HIV testing events coming soon to Regina
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
2 minutes ago
- National Post
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content
CTV News
2 minutes ago
- CTV News
York police charge doctor with two counts of sexual assault
Police in York Region have arrested a doctor on sexual assault charges. York's Criminal Investigations Bureau have charged a doctor with sexual assault after a victim reported two incidences. Police say the person attended a medical clinic on Markham Road. During the visit, the person said the doctor touched them in a sexual manner. The victim left immediately and reported the incident to the police. While telling police of the experience, the person also recalled a previous appointment at the same clinic in November 2023, when the doctor's actions were also inappropriate. At that time, the person didn't report the event because they believed the conduct might have been part of a legitimate medical procedure. Police are asking the public to review the photo of Dr. Saber Abdel Malouka Abdel Malak, 62, of Whitchurch-Stouffville who has been a physician for more than 30 years. Police say a sexual assault includes any non-consensual contact of a sexual nature. They encourage anyone who feels they may have been a victim to report the incident to the police. To make an online report click here. Anyone with information is asked to call the York Regional Police Special Victims Unit at 1-866-876-5423, ext. 7071. Anonymous tips can be made by calling Crime Stoppers at 1-800-222-TIPS.
Globe and Mail
32 minutes ago
- Globe and Mail
Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières
SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (OTC: FITY), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event will be broadcast on X (formerly Twitter), featuring Nobel Peace Prize recipient Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières (Doctors Without Borders) for the organization's groundbreaking humanitarian medical aid in crisis zones worldwide. Dr. Orbinski's involvement highlights the company's commitment to global health innovation. Viewers can access the video teleconference directly on X by following @Fifty1Labs or searching for the live stream at the scheduled time. The teleconference will showcase Fifty 1 Labs' world-class leadership team, including Dr. Orbinski as Senior Scientist, and provide insights into the company's strategic roadmap, with a focus on advancements in its subsidiary Fifty 1 AI Labs. Key talking points from the event include: AI-Driven Drug Repurposing and Functional Medicine Leadership: Fifty 1 AI Labs' proprietary AI platform accelerates the repurposing of off-patent compounds, reducing development costs and enabling personalized wellness solutions. This positions the company to capture significant market share in functional medicine, projected to grow at a 10.9% CAGR through 2030. Strategic Roadmap Pillars: The company's plan focuses on three core areas: (1) Innovation through a $1 million R&D investment to advance AI therapies for unmet needs in functional medicine; (2) Growth via a targeted $5–10 million biotech acquisition by July 2027 to expand the pipeline and market reach; and (3) Shareholder alignment with uplisting to OTCQB by Q1 2026 and NASDAQ thereafter, enhancing liquidity and visibility. Management Commitment and Alignment: The leadership team has demonstrated strong confidence by personally investing $350,000 in the company and deferring salaries until a $50 million valuation is achieved or within two years. This aligns executive incentives directly with shareholder value and supports the R&D budget and acquisition strategy. Expert Leadership Team: Led by CEO Paul Arora, a biotech veteran with successful exits in health tech, the team includes Nobel Peace Prize recipient James Orbinski (Senior Scientist), who accepted the 1999 Nobel Peace Prize for Médecins Sans Frontières and co-founded the Drugs for Neglected Diseases initiative (DNDi); Chief Medical Officer Nima Sakian, a pioneer in anti-aging and functional medicine; CTO Alind Gupta, an AI and health analytics expert; Scientific Advisors Edward Mills (founder of the award-winning TOGETHER Trial) and Kristian Thorlund (top 1% cited expert in AI and trial methodology); Strategic Advisor Louis Dron, specializing in AI for drug discovery; and Founder/President Brandon Spikes, a former NFL linebacker bringing wellness and athletic performance insights. Differentiation in AI Drug Development: Unlike traditional models, Fifty 1 AI Labs emphasizes off-patent repurposing with real-world clinical data and adaptive trials for faster, safer, and more affordable therapies. The team's global health and wellness expertise enables unique market positioning, including partnerships with leading universities for evidence-based supplements. Team Cohesion and Academic Rigor: With decades of collaboration across clinical, tech, and global health sectors, the team operates with trust and scientific rigor, leveraging academic partnerships for cutting-edge research and peer-reviewed decision-making. During the teleconference, the leadership team will address forward-looking strategies, including potential risks, and invite shareholders to submit questions post-event to IR@ for future engagement. A recording will be available on the company's website following the broadcast. "We are excited to share our transformative vision with shareholders," said Paul Arora, CEO of Fifty 1 Labs. "By harnessing AI to redefine preventative healthcare, we are not only pursuing exponential growth but also creating lasting value for our investors, partners, and patients." For more details on the teleconference or to access related materials, visit Shareholders are encouraged to tune in live on X at 12:00 PM EST on July 28, 2025. About Fifty 1 Labs, Inc. Fifty 1 Labs, Inc. (OTC: FITY) is a forward-thinking company dedicated to AI-driven innovations in functional medicine and wellness. Through its subsidiary Fifty 1 AI Labs, the company leverages artificial intelligence to repurpose drugs and develop personalized health solutions, targeting high-growth markets in biotech and preventative care. Investor Contact: Investor Relations Fifty 1 Labs, Inc. Email: IR@ Phone: (877) 505-5006 Website: Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's future financial and operating performance, business strategy, plans, objectives, and expectations regarding future events or performance. These statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. For additional details, refer to the company's filings with the Securities and Exchange Commission.
